Organon & Co. (OGN) — Fair Value Analysis

Base-case fair value (P50): $19.43 · Current price: $13.43 · Verdict: Undervalued

The Verdict on OGN

Based on our Monte Carlo simulations, ORGANON (OGN) is currently assessed as Fairly Valued. While the current price of $13.43 suggests a potential +44.7% to our median fair value (P50) of $19.43, this "Fairly Valued" verdict incorporates the full spectrum of simulated outcomes, balancing both upside potential and downside risks. This indicates that while there's a clear path to a higher valuation based on the median, the overall distribution of potential fair values means OGN isn't considered deeply undervalued at its current trading level.

How OGN stacks up against peers

OGN’s operational and financial health is currently categorized as "average" within its sector (n/a). This average quality tier influences the robustness and potential volatility of its fair value estimates. Companies with average quality may exhibit a wider dispersion in their Monte Carlo simulated outcomes, meaning while a median fair value of $19.43 is identified, the probability distribution might show significant potential in both a bull case and a bear case scenario. Investors should consider this average quality tier when evaluating the implied +44.7% from $13.43 to $19.43.

What this means for investors

For investors, OGN being "Fairly Valued" with a +44.7% to our P50 fair value of $19.43 suggests that while upside exists, it is not without corresponding risks that balance the overall outlook. The Monte Carlo analysis, which drives this assessment, models thousands of potential future scenarios, identifying a median target that is above the current $13.43. To fully understand the risk-reward profile, including detailed bear-case and bull-case targets, and the probability of achieving various outcomes, sign up for FairCurve to see the full bear/bull distribution and track OGN's fair value as new fundamentals are released.